p53 as a prognostic factor in stage I breast cancer

Abstract

SinaryAccumulation of the tumour-suppressor protein p53 in breast cancer is associated with several prognostic factors that indicate an aggressive, rapidly proliferating tumour with an unstable genome. To assess p53 accumulation in stage I breast cancer and to evaluate the prognostic value of both nuclear and cytoplasmic p53, 205 patients with node-negative breast cancer and tumour size Ess than or equal to 20 mm were examined. Immunohistochemistry was performed on frozen sections with the monoclonal antibodies PAb 1801 and DOI. Cllular p53 accumulation, within either the nucleus or the cytoplasm or in both, showed the same association with different pathobiological variables as nuclear accumulation alone. Eklven per cent of the tumours showed strong nuclear accumulation and were significantly correlated to age under 50 years, negative oestrogen receptor status, DNA aneuploidy, high S-phase fraction, high pathological grade and poor prognosis. The distant recurrence rate ratio was 6.2 (P=0.002). It is thus concluded that p53 accumulation is of prognostic value in early stage breast cancer.

Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up

“…The proportion of cancers with p53 mutation (20%), p53 allele loss (41%), p53 mRNA expression (54%) and overexpression (28%) or p53 protein expression (32%) are similar to the reported series (Cattoretti et al, 1988;Davidoff, 1991;Iwaya, 1991;Kovach et al, 1991;Osborne et al, 1991;Runnebaum et al, 1991;Varley et al, 1991;Vojtesek et al, 1992;Andersen et al, 1993;Barnes, 1993;Friedrichs, 1993;Martinazzi, 1993;Thorlacius et al, 1993;Tsuda et al, 1993;Marks et al, 1994;Bergh et al, 1995;Borressen et al, 1995;Stenmark-Askmalm et al, 1995).…”

Prognostic value of DNA ploidy in 653 Japanese women with node-negative breast cancer

“…2 It is, therefore, important to find a useful prognostic factor that could identify low-risk groups who do not require adjuvant therapy and high-risk groups who need adjuvant therapy among all patients with node-negative breast cancer. The size of the primary tumor and histologic grade have been considered to be useful prognostic factors in node-negative breast cancer, 3,4 while some additional biological factors, such as estrogen receptor status, 5 and the expression of the c-erbB2 oncogene 6 and the p53 gene 7 have also been analyzed in regard to their prognostic value in patients with node-negative breast cancer. The prognostic value of such findings, however, remains controversial, and few prognostic factors have yet been established for node-negative breast cancer.…”

“…8 In studies of such new biological parameters as estrogen receptor status, and the expression of the c-erbB2 oncogene and the p53 gene, the relationship between DNA ploidy and these biological parameters has been analyzed. [5][6][7] The prognostic value of DNA ploidy has also been extensively studied in Western women with node-negative breast cancer; however, the results have not been consistent. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Some studies have shown that patients with aneuploid tumors have a significantly worse clinical outcome, [9][10][11][12][13][14][15] whereas others have shown DNA ploidy to have no prognostic value.…”

Indicadores de Prognóstico em Câncer de Mama com Axila Negativa: Receptor de Estrógeno e Expressão de P53 e de c-erbB-2

“…Observaram-se ainda maior sobrevida e maior intervalo livre de doença em pacientes com RE positivo quando comparadas com as com tumores de mama com RE negativo e tumores pouco diferenciados 11,13,17 . Stenmark-Askmalm et al 29 estudaram 205 pacientes com câncer de mama com linfonodos axilares negativos, encontrando 11% de positividade para p53 em mulheres que apresentavam RE negativo e grau III, correlacionando tais achados com pior prognóstico. A associação entre a proteína p53 com o prognóstico de pacientes com câncer de mama e axila negativa também foi estudada por Iwaya et al 24 , no Japão, que relataram um estudo de tipo controle entre 32 mulheres que tiveram recidiva precoce de câncer de mama e 122 pacientes sem recidiva.…”